Raptor Pharmaceuticals Corp.
(Nasdaq: RPTP) reported disappointing results from a Phase 2b CyNCh
study of RP103 in children with biopsy-confirmed nonalcoholic
steatohepatits. The stock price plummeted $4.56 to $7.47.
Disappointing study results for Raptor Pharmaceuticals
September 14, 2015 at 07:19 AM EDT
